查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1700069

2032 年生物性骨材市场预测：按产品类型、分销管道、应用、最终用户和地区进行的全球分析

Orthobiologics Market Forecasts to 2032 - Global Analysis By Product Type (Bone Grafts, Growth Factors, Platelet-Rich Plasma (PRP), Stem Cells, Cell-Based Therapies and Other Product Types), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球生物性骨材市场预计在 2025 年达到 72 亿美元，到 2032 年将达到 112 亿美元，预测期内的复合年增长率为 6.5%。

生物性骨材是利用生物材料和物质来促进肌肉骨骼疾病的癒合和修復。这些治疗方法包括干细胞、富血小板血浆 (PRP)、生长因子和细胞外基质蛋白，这些可能来自身体或合成产生。在整形外科中，生物製药通常用于透过促进组织再生、减少发炎和加速癒合过程来治疗损伤和退化性疾病。对于关节、韧带、肌腱和骨骼受伤的患者来说，这种方法提供了一种比手术更自然的替代方法，有可能改善治疗效果并缩短恢復时间。

根据ISAPS全球调查，2022年整形外科医师实施的手术数量增加了11.2%。全球共实施了约1880万例非手术手术和1490万例手术手术，延续了过去四年41.3%的成长趋势。

微创手术需求不断成长

市场对微创手术的需求不断增长，因为与传统手术相比，微创手术恢復时间更短、併发症风险更低、术后疼痛更少。患者越来越青睐这些手术，因为它们可以治疗肌肉骨骼损伤，同时最大限度地减少对周围组织的损伤。随着技术的进步和认识的提高，PRP 和干细胞疗法等微创骨科生物疗法的应用预计将继续增长并改变整形外科的格局。

缺乏标准化

市场缺乏标准化带来了重大挑战，包括治疗结果不一致和安全问题。如果没有明确的指导方针，干细胞注射和富血小板血浆 (PRP) 等治疗方法的品质和效果可能会有很大差异，并为患者带来不可预测的结果。这种不一致会破坏患者的信任并阻碍其广泛采用。此外，缺乏标准化协议使监管监督变得复杂，并增加了未经证实或不安全的治疗方法进入市场并伤害患者的可能性。

再生医学意识不断增强

随着患者和医疗保健提供者认识到再生医学在治疗和组织修復方面的潜力，人们对再生医学的认识不断提高，这对市场产生了重大影响。再生疗法，例如干细胞疗法和富血小板血浆（PRP），为治疗肌肉骨骼损伤和退化性疾病提供了一个有希望的传统手术替代方案。随着教育和研究的进步，越来越多的人正在寻求这些创新治疗方法，以便更快地康復并取得更好的结果。这种日益增强的认识正在推动再生医学在骨科生物学应用中日益增长的需求和扩展。

治疗费用高昂

市面上治疗费用高昂，限制了许多患者获得这些先进疗法的机会，尤其是那些没有足够保险的患者。干细胞疗法和富血小板血浆 (PRP) 注射等昂贵治疗的经济负担可能导致一些患者放弃可能有益的治疗。这不仅造成了医疗保健机会的不平等，而且还减缓了生物性骨材的广泛应用。

COVID-19的影响：

COVID-19 疫情扰乱了供应链，推迟了选择性手术，并限制了患者接受治疗的机会，对市场产生了重大影响。许多整形外科诊所和医院暂停了非紧急护理，减少了对干细胞疗法和 PRP 注射等再生治疗的需求。此外，经济拮据和对感染风险的担忧导致患者推迟或放弃治疗。然而，疫情也可能加速人们对微创、非手术治疗的兴趣，进而推动未来的市场成长。

腰椎融合手术预计将成为预测期内最大的手术市场

腰椎融合部分包括骨移植和干细胞以促进脊椎骨的癒合和融合，预计在预测期内将占据最大的市场占有率。透过整合骨科生物疗法，腰椎融合旨在促进癒合、减少併发症并改善患者预后。随着微创技术越来越普及，脊椎外科再生疗法的需求预计会增加，为患者提供更好的復健选择。

预计牙科诊所部门在预测期内将实现最高的复合年增长率。

预计牙科诊所部门将在预测期内见证最高的成长率。这些生物疗法有助于促进组织再生、减少发炎并提高牙科手术的整体成功率。随着人们对再生医学认识的不断提高，越来越多的牙科专业人士将生物性骨材纳入他们的实践中，为患者提供先进的微创治疗选择，以实现更快的康復和更好的长期效果，从而推动了牙科行业的需求。

占比最大的地区：

在预测期内，由于医疗保健意识的提高，预计亚太地区将占据最大的市场占有率。日本、中国和印度等国家越来越多地采用干细胞疗法、富血小板血浆 (PRP) 和骨移植等治疗方法。医疗保健基础设施的成长和向微创治疗的转变正在推动对生物製药的需求。法律规范的改善和医疗研究和技术投资的增加也为市场提供了支持。

复合年增长率最高的地区：

预计北美地区在预测期内将呈现最高的复合年增长率。再生医学的技术进步，例如干细胞疗法、基因疗法和富血小板血浆 (PRP) 疗法，正在提高骨科生物疗法的有效性。此外，随着越来越多的患者和医疗保健专业人员了解骨生物学疗法的益处，包括加速癒合和减少对传统药物和手术的依赖，对这些治疗的需求正在增加。

免费客製化服务：

订阅此报告的客户可以享受以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球生物性骨材市场（依产品类型）

  • 骨移植
    • 自体移植
    • 同种异体移植
    • 合成骨移植
  • 生长因子
    • 骨形成蛋白（BMP）
    • 血小板衍生生长因子（PDGF）
    • 血管内皮生长因子（VEGF）
    • 转化生长因子β（TGF-B）
    • 胰岛素样生长因子（IGF）
  • 富血小板血浆（PRP）
  • 干细胞
    • 间质干细胞（MSCs）
    • 造血干细胞
    • 诱导性多功能干细胞（iPSC）
  • 细胞治疗方法
    • 自体细胞疗法
    • 同种异体细胞治疗
  • 其他产品类型

6. 全球生物性骨材市场（依分销管道）

  • 直销
  • 间接销售
  • 电商平台

7. 全球生物性骨材市场（按应用）

  • 颈椎融合手术
  • 腰椎融合手术
  • 胸椎融合术
  • 髋关节置换术
  • 肩关节重组手术
  • 人工植牙
  • 伤口癒合
  • 微骨折手术
  • 韧带修復
  • 其他用途

8. 全球生物性骨材市场（依最终用户划分）

  • 医院
  • 门诊手术中心
  • 整形外科诊所
  • 牙医诊所
  • 復健中心
  • 研究组织
  • 其他最终用户

9. 全球生物性骨材市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Bioventus LLC
  • Nuvasive, Inc.
  • Anika Therapeutics, Inc.
  • Alphatec Spine, Inc.
  • Medtronic plc
  • Stryker Corporation
  • Globus Medical, Inc.
  • Xtant Medical Holdings, Inc.
  • Sanofi SA
  • Orthofix Medical Inc.
  • Bone Therapeutics SA
  • RTI Surgical, Inc.
  • Kuros Biosciences Ltd.
  • Smith & Nephew plc
  • Integra LifeSciences Holdings Corporation
  • Seaspine Holdings Corporation
  • Arthrex, Inc.
Product Code: SMRC28972

According to Stratistics MRC, the Global Orthobiologics Market is accounted for $7.2 billion in 2025 and is expected to reach $11.2 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Orthobiologics is the use of biological materials and substances to promote healing and repair in musculoskeletal conditions. These therapies include stem cells, platelet-rich plasma (PRP), growth factors, and extracellular matrix proteins, which are derived from the body or synthesized. Orthobiologics are often used in orthopedics to treat injuries or degenerative diseases by stimulating tissue regeneration, reducing inflammation, and accelerating healing processes. This approach offers a more natural alternative to surgery, with the potential for improved outcomes and reduced recovery times for patients with joint, ligament, tendon, or bone injuries.

According to the ISAPS Global Survey, the number of procedures performed by plastic surgeons increased by 11.2% in 2022. About 18.8 million non-surgical and 14.9 million surgical procedures were performed worldwide, continuing the trend of a 41.3% increase over the last four years.

Market Dynamics:

Driver:

Growing demand for minimally invasive procedures

The growing demand for minimally invasive procedures in the market is driven by their ability to offer faster recovery times, reduced risk of complications, and less post-operative pain compared to traditional surgeries. Patients increasingly prefer these procedures due to their effectiveness in treating musculoskeletal injuries with minimal disruption to surrounding tissues. As technologies improve and awareness rises, the adoption of minimally invasive Orthobiologic treatments like PRP and stem cell therapies is expected to continue growing, transforming the landscape of orthopedic care.

Restraint:

Lack of standardization

The lack of standardization in the market poses significant challenges, including inconsistent treatment outcomes and safety concerns. Without clear guidelines, the quality and efficacy of therapies like stem cell injections and platelet-rich plasma (PRP) can vary widely, leading to unpredictable results for patients. This inconsistency undermines patient trust and can hinder widespread adoption. Additionally, the absence of standardized protocols complicates regulatory oversight, increasing the risk of unproven or unsafe treatments entering the market and potentially harming patients.

Opportunity:

Rising awareness of regenerative medicine

Rising awareness of regenerative medicine is significantly influencing the market, as patients and healthcare providers recognize its potential for healing and tissue repair. Regenerative treatments, such as stem cell therapy and platelet-rich plasma (PRP), offer promising alternatives to traditional surgeries, addressing musculoskeletal injuries and degenerative conditions. As education and research advance, more people are seeking out these innovative treatments for faster recovery and improved outcomes. This growing awareness is driving the increasing demand and expansion of regenerative medicine in orthobiologic applications.

Threat:

High cost of treatments

The high cost of treatments in the market limits access to these advanced therapies for many patients, particularly those without adequate insurance coverage. Expensive procedures like stem cell therapy or platelet-rich plasma (PRP) injections can be financially burdensome, leading some individuals to forgo potentially beneficial treatments. This not only creates inequities in healthcare access but also slows the widespread adoption of Orthobiologics, as patients may opt for more affordable, conventional treatments, even if they may not offer the same regenerative benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market by disrupting supply chains, delaying elective procedures, and limiting patient access to treatments. Many orthopedic clinics and hospitals paused non-emergency services, leading to a reduction in the demand for regenerative therapies like stem cell treatments and PRP injections. Additionally, financial constraints and concerns over infection risks led patients to delay or forgo treatments. However, the pandemic also accelerated interest in minimally invasive and non-surgical options, which may drive future growth in the market.

The lumbar fusion segment is expected to be the largest during the forecast period

The lumbar fusion segment is expected to account for the largest market share during the forecast period such as bone grafts or stem cells, to promote the healing and fusion of vertebrae in the lower back. By integrating orthobiologic therapies, lumbar fusion aims to enhance healing, reduce complications, and improve patient outcomes. As minimally invasive techniques gain traction, the demand for regenerative treatments in spinal surgery is expected to increase, offering better recovery options for patients.

The dental clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the dental clinics segment is predicted to witness the highest growth rate. These biologic therapies help accelerate tissue regeneration, reduce inflammation, and improve the overall success of dental surgeries. As awareness of regenerative medicine grows, more dental professionals are integrating Orthobiologics into their practice, providing patients with advanced, minimally invasive options for faster recovery and better long-term results, boosting the demand within the dental sector.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing healthcare awareness. Countries like Japan, China, and India are seeing greater adoption of treatments such as stem cell therapy, platelet-rich plasma (PRP), and bone grafts. Growing healthcare infrastructure, along with a shift towards minimally invasive procedures, is driving demand for Orthobiologics. The market is also supported by improving regulatory frameworks and increasing investments in medical research and technology.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. Technological advancements in regenerative medicine, including stem cell therapies, gene therapies, and platelet-rich plasma (PRP) treatments, have boosted the efficacy of orthobiologic treatments. These innovations have led to greater adoption among both patients and healthcare providers.Moreover, As more patients and healthcare professionals learn about the benefits of orthobiologic therapies, such as accelerated healing and reduced dependency on traditional drugs or surgeries, demand for these treatments has risen.

Key players in the market

Some of the key players in Orthobiologics Market include Bioventus LLC, Nuvasive, Inc., Anika Therapeutics, Inc., Alphatec Spine, Inc., Medtronic plc, Stryker Corporation, Globus Medical, Inc., Xtant Medical Holdings, Inc., Sanofi S.A., Orthofix Medical Inc., Bone Therapeutics SA, RTI Surgical, Inc. , Kuros Biosciences Ltd. , Smith & Nephew plc, Integra LifeSciences Holdings Corporation , Seaspine Holdings Corporation and Arthrex, Inc.

Key Developments:

In March 2025, Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis..

In March 2024, Stryker announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.

Product Types Covered:

  • Bone Grafts
  • Growth Factors
  • Platelet-Rich Plasma (PRP)
  • Stem Cells
  • Cell-Based Therapies
  • Other Product Types

Distribution Channels Covered:

  • Direct Sales
  • Indirect Sales
  • E-Commerce Platforms

Applications Covered:

  • Cervical Fusion
  • Lumbar Fusion
  • Thoracic Fusion
  • Hip Replacement
  • Shoulder Reconstruction
  • Dental Implants
  • Wound Healing
  • Microfracture Surgery
  • Ligament Repair
  • Other Applications

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
  • Dental Clinics
  • Rehabilitation Centers
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Orthobiologics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Bone Grafts
    • 5.2.1 Autografts
    • 5.2.2 Allografts
    • 5.2.3 Synthetic Bone Grafts
  • 5.3 Growth Factors
    • 5.3.1 Bone Morphogenetic Proteins (BMPs)
    • 5.3.2 Platelet-Derived Growth Factor (PDGF)
    • 5.3.3 Vascular Endothelial Growth Factor (VEGF)
    • 5.3.4 Transforming Growth Factor-beta (TGF-B)
    • 5.3.5 Insulin-like Growth Factor (IGF)
  • 5.4 Platelet-Rich Plasma (PRP)
  • 5.5 Stem Cells
    • 5.5.1 Mesenchymal Stem Cells (MSCs)
    • 5.5.2 Hematopoietic Stem Cells
    • 5.5.3 Induced Pluripotent Stem Cells (iPSCs)
  • 5.6 Cell-Based Therapies
    • 5.6.1 Autologous Cell Therapy
    • 5.6.2 Allogeneic Cell Therapy
  • 5.7 Other Product Types

6 Global Orthobiologics Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Direct Sales
  • 6.3 Indirect Sales
  • 6.4 E-Commerce Platforms

7 Global Orthobiologics Market, By Application

  • 7.1 Introduction
  • 7.2 Cervical Fusion
  • 7.3 Lumbar Fusion
  • 7.4 Thoracic Fusion
  • 7.5 Hip Replacement
  • 7.6 Shoulder Reconstruction
  • 7.7 Dental Implants
  • 7.8 Wound Healing
  • 7.9 Microfracture Surgery
  • 7.10 Ligament Repair
  • 7.11 Other Applications

8 Global Orthobiologics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers
  • 8.4 Orthopedic Clinics
  • 8.5 Dental Clinics
  • 8.6 Rehabilitation Centers
  • 8.7 Research Institutes
  • 8.8 Other End Users

9 Global Orthobiologics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Bioventus LLC
  • 11.2 Nuvasive, Inc.
  • 11.3 Anika Therapeutics, Inc.
  • 11.4 Alphatec Spine, Inc.
  • 11.5 Medtronic plc
  • 11.6 Stryker Corporation
  • 11.7 Globus Medical, Inc.
  • 11.8 Xtant Medical Holdings, Inc.
  • 11.9 Sanofi S.A.
  • 11.10 Orthofix Medical Inc.
  • 11.11 Bone Therapeutics SA
  • 11.11 RTI Surgical, Inc.
  • 11.13 Kuros Biosciences Ltd.
  • 11.14 Smith & Nephew plc
  • 11.15 Integra LifeSciences Holdings Corporation
  • 11.16 Seaspine Holdings Corporation
  • 11.17 Arthrex, Inc.

List of Tables

  • Table 1 Global Orthobiologics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Orthobiologics Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Orthobiologics Market Outlook, By Bone Grafts (2024-2032) ($MN)
  • Table 4 Global Orthobiologics Market Outlook, By Autografts (2024-2032) ($MN)
  • Table 5 Global Orthobiologics Market Outlook, By Allografts (2024-2032) ($MN)
  • Table 6 Global Orthobiologics Market Outlook, By Synthetic Bone Grafts (2024-2032) ($MN)
  • Table 7 Global Orthobiologics Market Outlook, By Growth Factors (2024-2032) ($MN)
  • Table 8 Global Orthobiologics Market Outlook, By Bone Morphogenetic Proteins (BMPs) (2024-2032) ($MN)
  • Table 9 Global Orthobiologics Market Outlook, By Platelet-Derived Growth Factor (PDGF) (2024-2032) ($MN)
  • Table 10 Global Orthobiologics Market Outlook, By Vascular Endothelial Growth Factor (VEGF) (2024-2032) ($MN)
  • Table 11 Global Orthobiologics Market Outlook, By Transforming Growth Factor-beta (TGF-B) (2024-2032) ($MN)
  • Table 12 Global Orthobiologics Market Outlook, By Insulin-like Growth Factor (IGF) (2024-2032) ($MN)
  • Table 13 Global Orthobiologics Market Outlook, By Platelet-Rich Plasma (PRP) (2024-2032) ($MN)
  • Table 14 Global Orthobiologics Market Outlook, By Stem Cells (2024-2032) ($MN)
  • Table 15 Global Orthobiologics Market Outlook, By Mesenchymal Stem Cells (MSCs) (2024-2032) ($MN)
  • Table 16 Global Orthobiologics Market Outlook, By Hematopoietic Stem Cells (2024-2032) ($MN)
  • Table 17 Global Orthobiologics Market Outlook, By Induced Pluripotent Stem Cells (iPSCs) (2024-2032) ($MN)
  • Table 18 Global Orthobiologics Market Outlook, By Cell-Based Therapies (2024-2032) ($MN)
  • Table 19 Global Orthobiologics Market Outlook, By Autologous Cell Therapy (2024-2032) ($MN)
  • Table 20 Global Orthobiologics Market Outlook, By Allogeneic Cell Therapy (2024-2032) ($MN)
  • Table 21 Global Orthobiologics Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 22 Global Orthobiologics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 23 Global Orthobiologics Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 24 Global Orthobiologics Market Outlook, By Indirect Sales (2024-2032) ($MN)
  • Table 25 Global Orthobiologics Market Outlook, By E-Commerce Platforms (2024-2032) ($MN)
  • Table 26 Global Orthobiologics Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global Orthobiologics Market Outlook, By Cervical Fusion (2024-2032) ($MN)
  • Table 28 Global Orthobiologics Market Outlook, By Lumbar Fusion (2024-2032) ($MN)
  • Table 29 Global Orthobiologics Market Outlook, By Thoracic Fusion (2024-2032) ($MN)
  • Table 30 Global Orthobiologics Market Outlook, By Hip Replacement (2024-2032) ($MN)
  • Table 31 Global Orthobiologics Market Outlook, By Shoulder Reconstruction (2024-2032) ($MN)
  • Table 32 Global Orthobiologics Market Outlook, By Dental Implants (2024-2032) ($MN)
  • Table 33 Global Orthobiologics Market Outlook, By Wound Healing (2024-2032) ($MN)
  • Table 34 Global Orthobiologics Market Outlook, By Microfracture Surgery (2024-2032) ($MN)
  • Table 35 Global Orthobiologics Market Outlook, By Ligament Repair (2024-2032) ($MN)
  • Table 36 Global Orthobiologics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 37 Global Orthobiologics Market Outlook, By End User (2024-2032) ($MN)
  • Table 38 Global Orthobiologics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 39 Global Orthobiologics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 40 Global Orthobiologics Market Outlook, By Orthopedic Clinics (2024-2032) ($MN)
  • Table 41 Global Orthobiologics Market Outlook, By Dental Clinics (2024-2032) ($MN)
  • Table 42 Global Orthobiologics Market Outlook, By Rehabilitation Centers (2024-2032) ($MN)
  • Table 43 Global Orthobiologics Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 44 Global Orthobiologics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.